Related Experiment Video
Updated: Jul 15, 2026
06:07
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
Published on: October 22, 2020
Smoking and a complement gene polymorphism interact in promoting cardiovascular disease morbidity and mortality
G J Arason1, J Kramer, B Blaskó
1Department of Immunology, Institute for Medical Laboratory Sciences, Landspítali University Hospital, Reykjavík, Iceland. garason@lsh.is
Clinical and Experimental Immunology
|April 12, 2007
Summary
The C4B*Q0 genotype significantly increases cardiovascular disease risk, especially when combined with smoking. This interaction accelerates the age-related decline of C4B*Q0 carriers, particularly after age 50.
Area of Science:
- Genetics
- Cardiovascular Disease Research
- Epidemiology
Background:
- The C4B*Q0 genotype is linked to increased risk of myocardial infarction and stroke.
- Smoking is a major risk factor for cardiovascular disease (CVD).
- The interaction between C4B*Q0 genotype and smoking requires investigation.
Purpose of the Study:
- To investigate the interaction between the C4B*Q0 genotype and smoking in relation to cardiovascular disease risk.
- To determine if smoking modifies the association between C4B*Q0 and CVD outcomes.
Main Methods:
- Two studies were conducted with participants from Iceland and Hungary.
- Smoking habits, C4A and C4B gene counts were assessed.
- C4B*Q0 carrier frequency was compared between cases and controls, stratified by smoking status.
Main Results:
- C4B*Q0 carrier frequency was significantly higher in smokers with angina pectoris, acute myocardial infarction (AMI), and severe coronary artery disease compared to controls.
- No significant difference in C4B*Q0 frequency was observed in non-smoking subjects.
- The age-associated decrease in C4B*Q0 was strongly associated with smoking, occurring after age 50 in smokers.
Conclusions:
- The C4B*Q0 genotype acts as a significant covariate with smoking in precipitating the risk for AMI and associated deaths.
- Smoking exacerbates the risk associated with the C4B*Q0 genotype.
- These findings highlight the critical interplay between genetic predisposition and environmental factors in CVD development.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...